Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial

被引：0

作者：

Thaci, Diamant ^{[1
]}

Griffiths, Christopher E. M. ^{[2
]}

Iversen, Lars ^{[3
]}

Peserico, Andrea ^{[4
]}

Pau-Charles, Ignasi ^{[5
]}

Blauvelt, Andrew ^{[6
]}

Reich, Kristian ^{[7
]}

机构：

[1] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[2] Univ Manchester, Manchester Acad Hlth Sci Ctr, Dept Dermatol, Manchester, Lancs, England

[3] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark

[4] Univ Padua, Dept Med DIMED, Clin Dermatol, Padua, Italy

[5] Almirall R&D, Barcelona, Spain

[6] Oregon Med Res Ctr, Portland, OR USA

[7] Univ Med Ctr Hamburg Eppendorf, Skinflammat Ctr, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

26874

引用

页码：AB119 / AB119

页数：1